NASDAQ: BEAT
Heartbeam Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their BEAT stock forecasts and price targets.

Forecast return on equity

Is BEAT forecast to generate an efficient return?

Company
-328.92%
Industry
11.45%
Market
268.46%
BEAT's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is BEAT forecast to generate an efficient return on assets?

Company
-229.99%
Industry
14.47%
BEAT is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

BEAT earnings per share forecast

What is BEAT's earnings per share in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.59
Avg 2 year Forecast
-$0.64
Avg 3 year Forecast
-$0.40

BEAT revenue forecast

What is BEAT's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$2.1M
Avg 2 year Forecast
$2.7M
Avg 3 year Forecast
$12.8M

BEAT vs Health Information Service Stocks

TickerPricePrice TargetUp/downsideConsensus
BEAT$1.85N/AN/A
FORA$2.24N/AN/A
EUDA$2.10N/AN/A
AMWL$5.22$9.67+85.19%Buy
ONMD$2.12N/AN/A

Heartbeam Stock Forecast FAQ

What is BEAT's earnings growth forecast for 2025-2027?

(NASDAQ: BEAT) Heartbeam's forecast annual earnings growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast earnings growth rate of 53.3%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 102.16%.

Heartbeam's earnings in 2025 is -$20,344,000.On average, 5 Wall Street analysts forecast BEAT's earnings for 2025 to be -$20,192,370, with the lowest BEAT earnings forecast at -$21,554,540, and the highest BEAT earnings forecast at -$16,572,497. On average, 4 Wall Street analysts forecast BEAT's earnings for 2026 to be -$22,048,627, with the lowest BEAT earnings forecast at -$21,856,482, and the highest BEAT earnings forecast at -$21,976,573.

In 2027, BEAT is forecast to generate -$13,755,516 in earnings, with the lowest earnings forecast at -$22,395,174 and the highest earnings forecast at -$4,323,260.

If you're new to stock investing, here's how to buy Heartbeam stock.

What is BEAT's revenue growth forecast for 2025-2027?

(NASDAQ: BEAT) Heartbeam's forecast annual revenue growth rate of N/A is not forecast to beat the US Health Information Services industry's average forecast revenue growth rate of 11.13%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 58.85%.

Heartbeam's revenue in 2025 is $0.On average, 5 Wall Street analysts forecast BEAT's revenue for 2025 to be $72,328,830, with the lowest BEAT revenue forecast at $0, and the highest BEAT revenue forecast at $216,163,011. On average, 4 Wall Street analysts forecast BEAT's revenue for 2026 to be $92,744,225, with the lowest BEAT revenue forecast at $53,800,572, and the highest BEAT revenue forecast at $133,300,523.

In 2027, BEAT is forecast to generate $437,472,760 in revenue, with the lowest revenue forecast at $420,316,965 and the highest revenue forecast at $450,339,606.

What is BEAT's forecast return on assets (ROA) for 2025-2027?

(NASDAQ: BEAT) forecast ROA is -229.99%, which is lower than the forecast US Health Information Services industry average of 14.47%.

What is BEAT's Earnings Per Share (EPS) forecast for 2025-2027?

(NASDAQ: BEAT) Heartbeam's current Earnings Per Share (EPS) is -$0.70. On average, analysts forecast that BEAT's EPS will be -$0.59 for 2025, with the lowest EPS forecast at -$0.63, and the highest EPS forecast at -$0.48. On average, analysts forecast that BEAT's EPS will be -$0.64 for 2026, with the lowest EPS forecast at -$0.64, and the highest EPS forecast at -$0.64. In 2027, BEAT's EPS is forecast to hit -$0.40 (min: -$0.65, max: -$0.13).

What is BEAT's forecast return on equity (ROE) for 2025-2027?

(NASDAQ: BEAT) forecast ROE is -328.92%, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.